Lyme and chikungunya passed key milestones in 2019. Significant value inflection expected in 2020 including Lyme Phase 2 data and partnering in addition to chikungunya entering Phase 3 clinical development
- Strong financial results in 2019
- Private traveler market sales expected to grow by up to 10% in 2020
- Key R&D Progress reported in 2019
- Major R&D milestones expected in 2020